←Opioid Reduction
Study register · detail Retrospektive Mirror-Image-Studie · Opioid Reduction · 2018

Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis

Bellnier et al. ·Mental Health Clinician
Clear benefit GRADE Very low 46 citations
Samplen = 29 Pat.
Duration3 months
EndpointEQ-5D / PQAS
Blindingn.a.
DesignRetrospektive Mirror-Image-Studie
Cannabinoidvollspektrum
Key finding

Medical cannabis significantly improved quality of life and pain intensity compared to baseline and reduced opioid consumption as well as treatment costs.

Summary

Retrospective mirror-image study in n=29 patients with chronic pain (medical cannabis in New York State); 3-month follow-up. Improvement in quality of life measured by EQ-5D (pre 36 → post 64, p<0.0001). Reduction in opioid consumption as well as cost savings in analgesic prescriptions. Adverse effects in 10% of participants.

P
PopulationAdults with chronic pain and MC-qualifying conditions in New York State, n=29
I
InterventionMedical cannabis (MC), 3 months, application not specified
O
OutcomeSignificant improvement in quality of life (EQ-5D: 36 → 64, p<0,0001) and pain reduction (PQAS paroxysmal: 6,76 → 2,04, p<0,0001); reduction in opioid consumption and analgesic costs; adverse effects in 10% of patients
Confidence in the evidence
Very low

The lowest GRADE level, the effect estimate remains uncertain.

Downgraded for
Imprecision
Quality profile
Sample size ★★★★★
Blinding —
Effect size Clear benefit
Citations / year ★★★★★
Authors
Bellnier T, Brown GW, Ortega TR
DOI 10.9740/mhc.2018.05.110↗
Design: Retrospektive Mirror-Image-Studie
Share
Indication
Further studies on Opioid Reduction
All studies →
S Nielsen et al. · 2022 · Neuropsychopharmacology
87 citations
Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies
Mixed Meta-Analyse

Umfassende SR+MA zu Opioid-sparenden Effekten von Cannabinoiden (k=92 Studien inkl. 15 laufender Trials). Präklinisch: ED50 von Morphin+THC 3.5-fach niedriger als Morphin allein (95% CI 2.04-6.03). Klinisch-akut: 3 RCTs fanden keine Opioid-Einsparung bei Akutschmerz. Krebsschmerz: k=4 RCTs, keine Reduktion der Opioid-Dosis (MD -3.8 mg, 95% CI -10.97 bis 3.37) oder Schmerz-Scores (MD 1.84, 95% CI -2.05 bis 5.72); mehr Nebenwirkungen vs. Placebo (RR 1.13, 95% CI 1.03-1.24). Chronischer Nicht-Krebsschmerz: 3 RCTs ohne Dronabinol-Effekt. Beobachtungsstudien: 39% berichteten Opioid-Stopp (95% CI 0.15-0.64), 85% Reduktion (95% CI 0.64-0.99). Präklinisch/beobachtend potenzial-zeigend, RCT-Evidenz widersprüchlich.

10.1038/s41386-022-01322-4 View study →
A Lake et al. · 2019 · PLOS Medicine
79 citations
Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: A longitudinal analysis
Clear benefit Kohortenstudie

Longitudinale Analyse zweier prospektiver Kohorten von PWUD mit chronischem Schmerz (n=1.152, Vancouver 2014-2017). 40% berichteten täglichen illicit Opioid-Gebrauch, 36% täglichen Cannabis-Gebrauch. Nach Adjustierung für demografische/Substanz-/Gesundheitsfaktoren war täglicher Cannabis-Gebrauch assoziiert mit signifikant niedrigerer Odds für täglichen illicit Opioid-Gebrauch (aOR 0.50, 95% CI 0.34-0.74, p<0.001). Hauptgründe für Cannabis: Schmerz (36%), Schlaf (35%), Stress (31%).

10.1371/journal.pmed.1002967 View study →
A Horlemann et al. · 2024 · Deutsche Gesellschaft für Schmerzmedizin
DGS-PraxisLeitlinie Cannabis in der Schmerzmedizin v2.0
No direction reported Leitlinie

DGS-PraxisLeitlinie v2.0 zu Cannabis in der Schmerzmedizin; enthält Empfehlungen zu Opioid-sparenden Strategien und Cannabis als Koanalgetikum bei chronischem Schmerz, basierend auf aktueller Evidenz und Expertenkonsens.

isbn:978-3-9817530-9-7 View study →

The impediment to action advances action. — Marcus Aurelius